Yale Cancer Center | Strategic Alliance Partners

November 26, 2018

Barbara A. Burtness, MD, discusses the impact that the KEYNOTE-048 data could have on the treatment of patients with head and neck squamous cell carcinoma.

November 01, 2018

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses frontline immunotherapy in head and neck cancer.

October 25, 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses long-term survival of patients with non–small cell lung cancer (NSCLC) treated with pembrolizumab (Keytruda).

September 06, 2018

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy in non-clear cell renal cancer.

August 27, 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses challenges with immunotherapy in non–small cell lung cancer.

August 10, 2018

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses key immunotherapy findings in non–small cell lung cancer, presented at the 2018 ASCO Annual Meeting.

August 03, 2018

Roy S. Herbst, MD, PhD, professor of medicine, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses tumor mutational burden (TMB) as a biomarker in non–small cell lung cancer (NSCLC).

July 11, 2018

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the bevacizumab (Avastin) biosimilar in lung cancer.

June 07, 2018

Anne Chiang, MD, PhD, discusses recent developments with immunotherapy and the overall outlook for the treatment landscape of small cell lung cancer.

June 01, 2018

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy combinations in renal cell carcinoma.

May 22, 2018

Mario Sznol, MD, professor of Medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the importance of clinical trials in renal cell carcinoma.

May 11, 2018

James B. Yu, MD, discusses techniques with radiation therapy, potential roadblocks, and the importance of genomic testing in treating patients with prostate cancer.

May 03, 2018

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses the potential benefit of primary tumor surgery for patients with breast cancer.

April 24, 2018

Alessandro D. Santin, MD, professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses the impact of trastuzumab (Herceptin) in patients with uterine serous carcinoma.

April 14, 2018

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the importance of a genetic counselor in the treatment of patients with prostate cancer.

April 12, 2018

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses surgery of the primary tumor in the metastatic setting of breast cancer.

April 12, 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses sequencing after therapy with osimertinib (Tagrisso) in EGFR-positive non–small cell lung cancer.

March 30, 2018

Alessandro D. Santin, MD, professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses the rationale for trastuzumab (Herceptin) in the treatment of patients with uterine serous carcinoma.

March 24, 2018

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses advancements in immunotherapy for the treatment of patients with renal cell carcinoma.

March 23, 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses osimertinib (Tagrisso) for the treatment of patients with non–small cell lung cancer.